284 filings
6-K
AFMD
Affimed N.V.
28 Mar 24
Affimed Reports 2023 Financial Results and Operational Progress
4:05pm
20-F
2023 FY
AFMD
Affimed N.V.
Annual report (foreign)
28 Mar 24
11:37am
6-K
AFMD
Affimed N.V.
11 Mar 24
Current report (foreign)
4:05pm
6-K
AFMD
Affimed N.V.
6 Mar 24
Affimed Announces 1-for-10 Reverse Stock Split
6:34am
SC 13G/A
Ridgeback Capital Investments L.P.
14 Feb 24
Affimed / Ridgeback Capital Investments ownership change
4:07pm
SC 13G/A
AFMD
Affimed N.V.
13 Feb 24
Affimed / 683 Capital Management ownership change
1:20pm
6-K
AFMD
Affimed N.V.
8 Jan 24
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype
4:45pm
6-K
AFMD
Affimed N.V.
8 Jan 24
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
8:11am
6-K
AFMD
Affimed N.V.
11 Dec 23
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1
6:10am
6-K
AFMD
Affimed N.V.
30 Nov 23
Current report (foreign)
7:00am
6-K
AFMD
Affimed N.V.
14 Nov 23
Unaudited consolidated interim statements of comprehensive loss
8:31am
6-K
AFMD
Affimed N.V.
4 Oct 23
Affimed Announces Listing Transfer to NASDAQ Capital Markets
6:40am
6-K
AFMD
Affimed N.V.
10 Aug 23
Unaudited consolidated interim statements of comprehensive loss
6:45am
SC 13G/A
BLK
Blackrock Inc.
7 Jul 23
Affimed / BlackRock ownership change
12:00am
6-K
AFMD
Affimed N.V.
22 Jun 23
Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board
6:41am
6-K
AFMD
Affimed N.V.
5 Jun 23
Data update from AFM24-101 phase 1/2 monotherapy study includes 15 patients from the EGFR mutant non-small cell lung cancer (NSCLC) cohort
6:04am
6-K
AFMD
Affimed N.V.
23 May 23
Unaudited consolidated statements of comprehensive loss
6:46am
6-K
AFMD
Affimed N.V.
22 May 23
Affimed Announces Annual General Meeting of Shareholders
6:49am
6-K
AFMD
Affimed N.V.
6 Apr 23
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding
5:07pm
S-8
AFMD
Affimed N.V.
23 Mar 23
Registration of securities for employees
4:53pm